1. Home
  2. CAAS vs CGTX Comparison

CAAS vs CGTX Comparison

Compare CAAS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAAS

China Automotive Systems Inc.

HOLD

Current Price

$4.79

Market Cap

128.8M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.10

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAS
CGTX
Founded
N/A
2007
Country
China
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.8M
110.8M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CAAS
CGTX
Price
$4.79
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
39.8K
943.2K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.87
$0.22
52 Week High
$5.15
$3.83

Technical Indicators

Market Signals
Indicator
CAAS
CGTX
Relative Strength Index (RSI) 64.85 44.22
Support Level $4.12 $1.01
Resistance Level $4.79 $1.19
Average True Range (ATR) 0.13 0.09
MACD 0.02 -0.02
Stochastic Oscillator 57.38 9.09

Price Performance

Historical Comparison
CAAS
CGTX

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: